Table 1 Univariate and multivariate Cox regression analysis of progression-free survival for patients with non-muscle-invasive tumours
From: Low ANXA10 expression is associated with disease aggressiveness in bladder cancer
Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
Variables | Categorisation | Hazard ratio | P -value | Hazard ratio | P -value |
Age | 5-year interval | 1.18 (1.06–1.32) | 0.003 | 1.09 (0.97–1.22) | 0.128 |
Sex | Male vs female | 0.92 (0.56–1.51) | 0.755 | ||
Tumour stage | Ta vs T1 | 2.58 (1.73–3.85) | <0.0001 | 0.82 (0.33–2.00) | 0.661 |
Histological grade | PUNLMP/low vs high | 3.02 (2.02–4.51) | <0.0001 | 2.92 (1.17–7.28) | 0.021 |
Tumour size | <3 vs >3 cm | 0.97 (0.60–1.56) | 0.900 | ||
BCG treatment | No BCG vs BCG | 0.57 (0.32–1.01) | 0.055 | 0.47 (0.25–0.89) | 0.020 |
Concomitant CISa | No CIS vs CIS | 1.41 (0.94–2.12) | 0.098 | 1.13 (0.71–1.80) | 0.601 |
Growth pattern | Papillary vs solid | 2.71 (1.40–5.25) | 0.003 | 1.56 (0.79–3.09) | 0.201 |
ANXA10 nuclear % | Low vs medium | 0.49 (0.30–0.80) | 0.005 | 0.59 (0.34–1.02) | 0.058 |
Low vs high | 0.25 (0.13–0.50) | <0.0001 | 0.35 (0.17–0.70) | 0.003 | |
